Cell cycle inhibitors make progress

J Natl Cancer Inst. 2014 Jul 8;106(7):dju221. doi: 10.1093/jnci/dju221. Print 2014 Jul.
No abstract available

Publication types

  • News

MeSH terms

  • Aminopyridines / pharmacology*
  • Aminopyridines / therapeutic use*
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use*
  • Benzimidazoles / pharmacology*
  • Benzimidazoles / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Cell Cycle / drug effects*
  • Clinical Trials, Phase I as Topic
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
  • Female
  • Humans
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use*
  • Proto-Oncogene Proteins / drug effects
  • Proto-Oncogene Proteins p21(ras)
  • Purines / pharmacology
  • Purines / therapeutic use
  • Pyridines / pharmacology*
  • Pyridines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Receptors, Estrogen / metabolism
  • ras Proteins / drug effects

Substances

  • Aminopyridines
  • Antineoplastic Agents
  • Benzimidazoles
  • KRAS protein, human
  • Piperazines
  • Proto-Oncogene Proteins
  • Purines
  • Pyridines
  • Receptors, Estrogen
  • abemaciclib
  • CDK4 protein, human
  • CDK6 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • palbociclib
  • ribociclib